Levels of soluble CD155 (sCD155) were significantly higher in the sera of 262 patients with various cancers, including lung, esophageal, gastric, colorectal, bile-duct, pancreatic, breast, ovarian, endometrial, and cervical cancers compared with healthy donors, suggesting that sCD155 could be a potential pan-tumor biomarker [12]. This evidence concerns the gene PVR and neoplasm.